Journal ArticleDOI
Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review
Maxine Sun,Shahrokh F. Shariat,Christopher Cheng,Vincenzo Ficarra,Masaru Murai,Stéphane Oudard,Allan J. Pantuck,Richard Zigeuner,Pierre I. Karakiewicz +8 more
TLDR
Several prognostic factors can help discriminate between favourable and unfavourable RCC phenotypes, and several clinical, pathologic, and biologic markers have been tested and validated and they are used in predictive and prognostic models.About:
This article is published in European Urology.The article was published on 2011-10-01. It has received 286 citations till now. The article focuses on the topics: Biologic marker & Renal cell carcinoma.read more
Citations
More filters
Journal ArticleDOI
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
Börje Ljungberg,Karim Bensalah,Steven E. Canfield,Saeed Dabestani,Fabian Hofmann,Milan Hora,Markus A. Kuczyk,Thomas B. Lam,Lorenzo Marconi,Axel S. Merseburger,Peter F.A. Mulders,Thomas Powles,Michael Staehler,Alessandro Volpe,Axel Bex +14 more
TL;DR: The 2014 RCC guideline has been updated by a multidisciplinary panel using the highest methodological standards, and provides the best and most reliable contemporary evidence base for RCC management.
Journal ArticleDOI
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Bernard Escudier,Camillo Porta,Manuela Schmidinger,Nathalie Rioux-Leclercq,Axel Bex,Vincent Khoo,Vincent Khoo,V. Gruenvald,Alan Horwich +8 more
TL;DR: RCC appears to be more common in patients with obesity, end-stage renal failure, acquired renal cystic disease and tuber-ous sclerosis, and severalautosomal dominant syndromes are described, each with a dis-tinct genetic basis and phenotype.
Journal ArticleDOI
Validation of the pre-treatment neutrophil–lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients
Martin Pichler,Georg C. Hutterer,Caroline Stoeckigt,Thomas F. Chromecki,Tatjana Stojakovic,Silvia Golbeck,Katharina Eberhard,Armin Gerger,Sebastian Mannweiler,Karl Pummer,Richard Zigeuner +10 more
TL;DR: Regarding patients’ OS, an increased NLR represented an independent risk factor, which might reflect a higher risk for severe cardiovascular and other comorbidities, and adding the NLR to well-established prognostic models such as the Leibovich prognosis score might improve their predictive ability.
Journal ArticleDOI
Prognostic factors and prognostic models for renal cell carcinoma: a literature review.
TL;DR: Several factors and models predict prognosis of localised and metastatic RCC, which represent valuable tools to provide estimates of clinically important endpoints, but their accuracy should be improved further.
Journal ArticleDOI
The translational potential of microRNAs as biofluid markers of urological tumours
TL;DR: Qualitative and analytical pitfalls exist and require addressing to enable future translation of the laboratory findings regarding miRNAs as biomarkers into clinical practice in bladder cancer, kidney cancer, prostate cancer and testicular cancer.
References
More filters
Journal ArticleDOI
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Robert J. Motzer,Thomas E. Hutson,Piotr Tomczak,M. Dror Michaelson,Ronald M. Bukowski,Olivier Rixe,Stéphane Oudard,Sylvie Negrier,Cezary Szczylik,Sindy T. Kim,Isan Chen,Paul Bycott,Charles M. Baum,Robert A. Figlin +13 more
TL;DR: Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those receiving interferon alfa.
Journal ArticleDOI
Sorafenib in advanced clear-cell renal-cell carcinoma.
Bernard Escudier,Tim Eisen,Walter M. Stadler,Cezary Szczylik,Stéphane Oudard,Michael Siebels,Sylvie Negrier,Christine Chevreau,Ewa Solska,Apurva A. Desai,Frederic Rolland,Tomasz Demkow,Thomas E. Hutson,Martin Gore,Scott Freeman,Brian Schwartz,M. Shan,Ronit Simantov,Ronald M. Bukowski +18 more
TL;DR: As compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom previous therapy has failed; however, treatment is associated with increased toxic effects.
Journal ArticleDOI
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion
Haidong Dong,Scott E. Strome,Diva R. Salomao,Hideto Tamura,Fumiya Hirano,Dallas B. Flies,Patrick C. Roche,Jun Lu,Gefeng Zhu,Koji Tamada,Vanda A. Lennon,Esteban Celis,Lieping Chen +12 more
TL;DR: It is reported here that, except for cells of the macrophage lineage, normal human tissues do not express B7-H1 and the findings have implications for the design of T cell–based cancer immunotherapy.
Journal ArticleDOI
Upstream and downstream of mTOR
Nissim Hay,Nahum Sonenberg +1 more
TL;DR: Both the upstream components of the signaling pathway(s) that activates mammalian TOR (mTOR) and the downstream targets that affect protein synthesis are described.
Journal ArticleDOI
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
Gary R. Hudes,Michael A. Carducci,Piotr Tomczak,Janice P. Dutcher,Robert A. Figlin,Anil Kapoor,Elzbieta Staroslawska,Jeffrey A. Sosman,David F. McDermott,Istvan Bodrogi,Zoran Kovacevic,Vladimir Lesovoy,Ingo G.H. Schmidt-Wolf,Olga Barbarash,Erhan Gokmen,Timothy O'Toole,Stephanie Lustgarten,Laurence Moore,Robert J. Motzer +18 more
TL;DR: As compared with interferon alfa, temsirolimus improved overall survival among patients with metastatic renal-cell carcinoma and a poor prognosis.
Related Papers (5)
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
Daniel Y.C. Heng,Wanling Xie,Meredith M. Regan,Mark Andrew Warren,Ali Reza Golshayan,Chakshu Sahi,Bernhard J. Eigl,J. Dean Ruether,Tina Cheng,Scott North,Peter Venner,Jennifer J. Knox,Kim N. Chi,Christian Kollmannsberger,David F. McDermott,William Oh,Michael B. Atkins,Ronald M. Bukowski,Brian I. Rini,Toni K. Choueiri +19 more
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer,Thomas E. Hutson,Piotr Tomczak,M. Dror Michaelson,Ronald M. Bukowski,Stéphane Oudard,Sylvie Negrier,Cezary Szczylik,Roberto Pili,Georg A. Bjarnason,Xavier Garcia-del-Muro,Jeffrey A. Sosman,Ewa Solska,George Wilding,John A. Thompson,Sindy T. Kim,Isan Chen,Xin Huang,Robert A. Figlin +18 more